ClinicalTrials.gg
WithdrawnNCT07357740Updated Jul 9, 2026

A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes

A Phase 2 interventional study of CagriSema and Placebo CagriSema in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Withdrawn at 61 sites in 8 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Why this study was withdrawn
The study is withdrawn due to strategic reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 4 of them phase 3. cagrilintide · Diabetes Mellitus, Type 2.

Enrollment
15th of 15
0 · median 274
Started
2026
with 3 others
Phase 2
4 of 15
none open now
Registered
13th of 15
by date
Lead sponsor
15 of 15
Novo Nordisk A/S

Among the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, this one is the 15th largest by enrollment, is one of 4 that started in 2026, is one of 4 in phase 2, and was the 13th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cagrilintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study is being done to look at how well a study medicine called CagriSema helps people with diabetes lower their blood sugar. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. The study will last for about 38 weeks.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female (sex assigned at birth, inclusive of all gender identities).
  • Age 18-64 years (both inclusive) at the time of signing the .
  • Diagnosed with type 2 diabetes mellitus greater than or equal to (>=) 180 days before screening.
  • (HbA1c) 7.0-10.5 percent (%) (53-91 [millimoles per mole] mmol/mol) (both inclusive) as determined by the central laboratory at screening.
  • Stable daily dose >= 90 days before screening of metformin at effective or maximum tolerated dose as judged by the investigator.
  • (BMI) between 25.0 and 39.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening.

Exclusion criteria

Exclusion Criteria:

  • Renal impairment with estimated (eGFR) \< 30 millilitre per minute per 1.73 square metre (mL/min/1.73 m\^2) as determined by the central laboratory at screening.
  • Treatment with any anti-diabetic or anti-obesity medication (irrespective of indication) other than stated in the inclusion criteria within 90 days before screening.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation.
  • Previous exposure to CagriSema in a clinical study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    CagriSema in device 1 + Placebo CagriSema B in device 2

    Participants will receive CagriSema in device 1 followed by placebo matched to CagriSema B in device 2 subcutaneously once weekly in a dose escalation manner.

    Drug: CagriSema · Drug: Placebo CagriSema

  • Experimental
    CagriSema B in device 2 + Placebo CagriSema in device 1

    Participants will receive CagriSema B in device 2 followed by placebo matched to CagriSema in device 1 subcutaneously once weekly in a dose escalation manner.

    Drug: CagriSema · Drug: Placebo CagriSema

Interventions

  • Cagrilintide and Semaglutide will be administered subcutaneously using device 1 or device 2.

  • DrugPlacebo CagriSema

    Placebo matched to Cagrilintide and Placebo matched to Semaglutide will be administered subcutaneously using device 1 or device 2.

This study also gives Semaglutide. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Change in glycated haemoglobin (HbA1c)

    Measured as percentage-points (%-points).

    Time frame: Baseline to week 28

Secondary outcomes

  1. Weekly average cagrilintide (total) and semaglutide concentration (Cavg) based on population pharmacokinetic analyses

    Measured in nanomoles per litre (nmol/L).

    Time frame: From baseline to week 28

  2. Change in HbA1c

    Measured as %-points.

    Time frame: From baseline to week 28

  3. Number of Treatment Emergent Adverse Events (TEAEs)

    Measured as count of events.

    Time frame: From baseline to week 35

  4. Number of clinically significant hypoglycaemic episodes (level 2) (less than [<] 3.0 millimoles per litre [mmol/L]), confirmed by blood glucose (BG) meter, or severe hypoglycaemic episodes (level 3)

    Measured as count of episodes.

    Time frame: From baseline to week 35

07

Study locations

61 sites
  • Arkansas Clinical Research
    Little Rock, Arkansas 72205, United States
  • Paradigm Clinical Research
    San Diego, California 92108, United States
  • Encompass Clinical Research_Spring Valley
    Spring Valley, California 91978, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Future Medical Research
    Longwood, Florida 32750, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • Clinical Site Partners Kendall Flourish Research
    Miami, Florida 33186, United States
  • West Orange Endocrinology
    Ocoee, Florida 34761, United States
  • Center for Diab,Obes & Metab
    Pembroke Pines, Florida 33024, United States
  • American Research Centers of Florida
    Pembroke Pines, Florida 33027, United States
  • Hope Clin Res & Wellness
    Conyers, Georgia 30094, United States
  • Elevate Clinical Research
    Gurnee, Illinois 60031, United States
  • Accellacare of Duly Oak Lawn
    Oak Lawn, Illinois 60453, United States
  • KDCILM, LLC & Accellacare US, Inc.
    Wilmington, North Carolina 28401, United States
  • Advanced Medical Research - Maumee
    Maumee, Ohio 43537, United States
  • Clinical Res Collaborative
    Cumberland, Rhode Island 02864, United States
  • Clinical Research Associates
    Nashville, Tennessee 37203, United States
  • The Endocrine Center
    Houston, Texas 77079, United States
  • Radiance Clinical Research
    Lampasas, Texas 76550, United States
  • Quality Research Inc
    San Antonio, Texas 78209, United States
  • Medrasa Clinical Research
    Sherman, Texas 75092, United States
  • Sanos Clinic - Vejle
    Vejle, Region Syddanmark 7100, Denmark
  • Sanos Clinic - Gandrup
    Gandrup, 9362, Denmark
  • Sanos Clinic - Herlev
    Herlev, 2730, Denmark
  • Regionshospitalet Viborg - Karkirurgisk Afsnit
    Viborg, 8800, Denmark
  • Athens Medical Center S.A. (Iatriko Psychicou) - Department of Internal Medicine & Metabolic Diseases
    Athens, 11525, Greece
  • General Hospital Of Thessaloniki Papageorgiou - 3rd Department of Internal Medicine
    Efkarpia, 564 29, Greece
  • General University Hospital Of Patras - Endocrinology Department
    Pátrai, 265 04, Greece
  • Ippokratio General Hospital Of Thessaloniki - 2nd Propaedeutic Department of Internal Medicine
    Thessaloniki, 546 42, Greece
  • Geniko Nosokomeio Thessalonikis George Papanikolaou - Internal Medicine and Diabetes Department
    Thessaloniki, 570 10, Greece
  • Thermi Clinic S.A. - Diabetes and Internal Medicine Department
    Thessaloniki, 57001, Greece
  • Hospital Tengku Ampuan Afzan
    Kuantan, Pahang 25100, Malaysia
  • Hospital Miri
    Miri, Sarawak 98000, Malaysia
  • Hospital Kuala Lumpur
    Kuala Lumpur, 50586, Malaysia
  • Hospital Melaka
    Malacca, 75400, Malaysia
  • Hospital Seberang Jaya
    Pulau Pinang, 13700, Malaysia
  • CHC Zvezdara, Clinical department for endocrinology
    Belgrade, 11000, Serbia
  • Endocrinology, Diabetes and Metabolism Diseases Clinic
    Belgrade, 11000, Serbia
  • Clinical Centre Kragujevac, Internal Diseases Clinic, Endocrinology department
    Kragujevac, 34000, Serbia
  • University Clinical Centre Nis
    Niš, 18 000, Serbia
  • Diakom, spol. s r.o.
    Poprad, 05801, Slovakia
  • MED-DIA CENTRUM s.r.o.
    Považská Bystrica, 01701, Slovakia
  • DIALIPID, s.r.o.
    Prešov, 080 01, Slovakia
  • iDia s. r. o.
    Žiar nad Hronom, 965 01, Slovakia
  • MEDIVASA, s.r.o., Diabetologicka ambulancia
    Žilina, 010 01, Slovakia
  • Centro Periferico De Especialidades Bola Azul
    Almería, 04009, Spain
  • EBA Vallcarca SLP
    Barcelona, 08023, Spain
  • CAPSBE_CAP Ernest LLuch
    Barcelona, 08028, Spain
  • Hospital Vall d'Hebron
    Barcelona, 08035, Spain
  • Centro de Salud Cabra Matrona Antonia Mesa
    Cabra, 14940, Spain
  • CAP Alhambra
    L'Hospitalet de Llobregat, 08920, Spain
  • Althaia Xarxa Assistencial Universitaria De Manresa Fundacio Privada
    Manresa, 08243, Spain
  • Centro de Salud Monzón Urbano
    Monzón, 22400, Spain
  • Centro de Salud Pola de Siero
    Pola de Siero, 33510, Spain
  • Centro de Salud San Juan de la Cruz
    Pozuelo de Alarcón, 28223, Spain
  • Clínica Nuevas Tecnologías en Diabetes y Endocrinología
    Seville, 41003, Spain
  • Phramongkutklao Hospital
    Bangkok, 10400, Thailand
  • Siriraj Hospital
    Bangkok, 10700, Thailand
  • RIHES-CMU_Research Institute for Health Sciences
    Chiang Mai, 50200, Thailand
  • Thammasat Hospital_CRC
    Pathum Thani, 12120, Thailand
  • Songklanagarind Hospital
    Songkhla, 90110, Thailand
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Aug 2027, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2026
First posted
Jan 22, 2026
StartEst.
Aug 27, 2026
Primary completionEst.
Aug 25, 2027
CompletionEst.
Oct 13, 2027
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07357740
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 22, 2026
Start date
Aug 27, 2026 (estimated)
Primary completion
Aug 25, 2027 (estimated)
Completion
Oct 13, 2027 (estimated)
Last update
Jul 9, 2026

Study contacts

Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion